Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pfizer Inc (PFE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 213,866,704
  • Shares Outstanding, K 5,947,350
  • Annual Sales, $ 52,824 M
  • Annual Income, $ 7,215 M
  • 36-Month Beta 1.00
  • Price/Sales 4.05
  • Price/Cash Flow 10.64
  • Price/Book 3.66

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.07 +8.74%
on 08/23/17
36.21 -0.69%
on 09/20/17
+2.81 (+8.48%)
since 08/22/17
3-Month
32.32 +11.26%
on 08/21/17
36.21 -0.69%
on 09/20/17
+1.90 (+5.58%)
since 06/22/17
52-Week
29.83 +20.55%
on 11/03/16
36.21 -0.69%
on 09/20/17
+1.81 (+5.30%)
since 09/22/16

Most Recent Stories

More News
Pfizer-Merck KGaA Skin Cancer Drug Bavencio Gets EU Approval

Pfizer and German partner Merck KGaA's Bavencio secures an EU approval for metastatic Merkel cell carcinoma. The company also expects to make the drug commercially available within a month.

AZN : 33.95 (+3.47%)
MRK : 65.13 (-0.72%)
KITE : 179.30 (-0.04%)
PFE : 35.96 (-0.03%)
Dow 30 Stock Roundup: BA Wins $600M Air Force Contract, JPM Invests in Bill.com

The Dow mopped up gains over the week, buoyed by announcements from the Federal Reserve.

AAPL : 151.89 (-0.98%)
JPM : 94.83 (-0.21%)
JNJ : 131.39 (-0.27%)
MRK : 65.13 (-0.72%)
PG : 92.24 (-0.43%)
FB : 170.54 (-0.33%)
PFE : 35.96 (-0.03%)
BA : 256.45 (+0.16%)
Cancer Space Update: Mixed Week for Pfizer, Roche Falters

Roche again disappointed this week with two studies on Tecentriq being put on partial hold while Pfizer's Bavencio received approval in Europe. TESARO's Zejula moved a step closer to approval.

MRK : 65.13 (-0.72%)
KPTI : 10.63 (+1.43%)
TSRO : 119.04 (+0.31%)
TEVA : 17.19 (+0.23%)
RHHBY : 32.0200 (-0.06%)
PFE : 35.96 (-0.03%)
Pharma Stock Roundup: Pfizer Files Suit against J&J, Supernus Hit by Study Update

Industry heavyweights like Pfizer (PFE) and Johnson & Johnson were in the news this week related to a lawsuit while Glaxo got FDA approval for a key drug.

JNJ : 131.39 (-0.27%)
SUPN : 39.00 (-1.02%)
TEVA : 17.19 (+0.23%)
RHHBY : 32.0200 (-0.06%)
PFE : 35.96 (-0.03%)
GSK : 40.58 (+0.62%)
BMY : 63.36 (+0.05%)
National Sickle Cell Disease Poll of African Americans Dispels Long-Held Views

Pfizer Inc. (NYSE:PFE), the National Newspaper Publishers Association (NNPA), and scholars from Howard University today announced results from a new national poll designed to deepen understanding...

PFE : 35.96 (-0.03%)
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer Inc. invites investors and the general public to listen to a discussion with Liz Barrett, Global President, Oncology, and Chris Boshoff, Senior Vice President and Head, Immuno-Oncology,...

PFE : 35.96 (-0.03%)
Pfizer Sues J&J, Accuses it of Preventing Inflectra Uptake

Pfizer (PFE) filed a lawsuit in a U.S. district court alleging that J&J is resorting to anticompetitive practices to prevent uptake of Inflectra.

JNJ : 131.39 (-0.27%)
MRK : 65.13 (-0.72%)
AMGN : 185.76 (-0.47%)
PFE : 35.96 (-0.03%)
Stock Market News For Sep 21, 2017

Markets closed mostly higher on Wednesday after the Federal Reserve announced trimming of its balance sheet from October.

C : 71.40 (-0.50%)
PNC : 133.43 (+0.06%)
BAC : 25.02 (-0.56%)
JPM : 94.83 (-0.21%)
GS : 231.03 (-0.11%)
PFE : 35.96 (-0.03%)
MCD : 158.91 (-0.08%)
National Sickle Cell Disease Poll of African Americans Dispels Long-Held Views

Pfizer Inc. (NYSE:PFE), the National Newspaper Publishers Association (NNPA), and scholars from Howard University today announced results from a new national poll designed to deepen understanding and gauge...

PFE : 35.96 (-0.03%)
Can Pfizer (PFE) Prove to be an Apt Value Investment?

Let's find out if Pfizer, Inc. (PFE) stock is a good choice for value-oriented investors right now

PFE : 35.96 (-0.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional...

See More

Support & Resistance

2nd Resistance Point 36.30
1st Resistance Point 36.13
Last Price 35.96
1st Support Level 35.78
2nd Support Level 35.60

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.